To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC's national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. Viral genomic sequences are analyzed and classified as a particular variant. The proportions of variants in a population are estimated nationally, by HHS region, and by jurisdiction. The thousands of sequences analyzed every week through CDC’s national genomic sequencing and bioinformatics efforts fuel this comprehensive and population-based U.S. surveillance system established to identify and monitor the spread of variants.
For more information on how these data are generated and used to provide estimates of variant proportions, please see the following references:
- Paul P, France AM, Aoki Y, et al. Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020–May 2021. MMWR Morb Mortal Wkly Rep 2021;70:846–850. DOI: http://dx.doi.org/10.15585/mmwr.mm7023a3
- Lambrou AS, Shirk P, Steele MK, et al. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:206–211. DOI: http://dx.doi.org/10.15585/mmwr.mm7106a4